| Followers | 2583 |
| Posts | 329774 |
| Boards Moderated | 23 |
| Alias Born | 04/12/2001 |
Thursday, February 15, 2024 6:07:42 PM
There's also this from Hindenburg:
Disclosure Insight (DI) is an investigative organization that uses Freedom of Information Act requests to discover whether companies are the subject of undisclosed SEC investigations.
According to DI, Renovaro has been the subject of an undisclosed SEC investigation since November 2020, which it confirmed as still ongoing as of December 21st, 2023. DI summed up their take on Renovaro as follows:
“We have zero confidence in the management and board of a company with this risk profile that steadfastly refuses to disclose an underlying SEC investigation our work keeps confirming as ongoing.”:
https://hindenburgresearch.com/renovaro/
Disclosure Insight (DI) is an investigative organization that uses Freedom of Information Act requests to discover whether companies are the subject of undisclosed SEC investigations.
According to DI, Renovaro has been the subject of an undisclosed SEC investigation since November 2020, which it confirmed as still ongoing as of December 21st, 2023. DI summed up their take on Renovaro as follows:
“We have zero confidence in the management and board of a company with this risk profile that steadfastly refuses to disclose an underlying SEC investigation our work keeps confirming as ongoing.”:
https://hindenburgresearch.com/renovaro/
Recent LNAI News
- Federal Judge Orders Expedited Discovery to Identify 'John Doe' Defendants 'Naked' Short-Sellers of Lunai Common Stock • PR Newswire (US) • 05/22/2026 01:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2026 01:15:29 PM
- LUNAI BIOWORKS, INC. ANNOUNCES REVERSE STOCK SPLIT • PR Newswire (US) • 05/20/2026 01:15:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2026 08:46:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2026 08:45:41 PM
- CNS Drug Delivery Technologies Are Reshaping Alzheimer's and Biodefense Research • InvestorsHub NewsWire • 05/13/2026 01:00:00 PM
- CNS Drug Delivery Technologies Are Reshaping Alzheimer’s and Biodefense Research • GlobeNewswire Inc. • 05/13/2026 12:30:00 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 05/11/2026 09:30:26 PM
- Lunai Bioworks Completes $20 Million Preferred Issuance to Acquire CNS Delivery and Neurotherapeutic IP • PR Newswire (US) • 05/04/2026 01:35:00 PM
- Form DEFR14A - Revised definitive proxy soliciting materials • Edgar (US Regulatory) • 05/01/2026 09:18:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/01/2026 09:17:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/28/2026 09:30:26 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/28/2026 09:00:31 PM
- Lunai Bioworks Unit Signs Preliminary Deal with Geneial on Rare Disease Data Collaboration • IH Market News • 04/15/2026 02:54:51 PM
- Lunai Bioworks (NASDAQ: LNAI) and Geneial Sign LOI to Build Rare Disease Patient Cohorts for Pharma Partnerships • PR Newswire (US) • 04/15/2026 01:10:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/13/2026 09:15:39 PM
- Lunai Bioworks unit secures defense collaboration for AI chemical threat platform • IH Market News • 04/07/2026 01:44:38 PM
- Lunai Bioworks (NASDAQ: LNAI) Secures First Revenue-Generating Defense Collaboration Through BioSymetrics, Deploying AI Platform for Chemical Threat Assessment; Additional Engagements Under Discussion • PR Newswire (US) • 04/07/2026 01:05:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/02/2026 09:01:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/30/2026 09:35:01 PM
- Lunai Bioworks to acquire CNS drug delivery platform and Alzheimer’s assets for $20M • IH Market News • 03/26/2026 03:21:42 PM
- Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring BBB Delivery Platform for CNS Alzheimer's Therapies with Broad CNS Delivery Applications • PR Newswire (US) • 03/26/2026 12:50:00 PM
- Lunai Bioworks (NASDAQ: LNAI) Launches National Chemical Defense Consortium Targeting $400M-$1.2B U.S. Countermeasure Programs; 3-Year AI Antidote Development Model • PR Newswire (US) • 03/19/2026 01:57:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 09:46:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2026 09:33:21 PM
